Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)

This grant opportunity (PAR-25-036) from NIH supports the development and application of PET and SPECT imaging ligands as biomarkers. The goal is to advance drug discovery and improve understanding of the pathophysiology of CNS disorders, with an optional clinical trial component.